Author: Ouahrouch, Abdelaaziz; Taourirte, Moha; Schols, Dominique; Snoeck, Robert; Andrei, Graciela; Engels, Joachim W.; Lazrek, Hassan B.
Title: Design, Synthesis, and Antiviral Activity of Novel Ribonucleosides of 1,2,3-Triazolylbenzyl-aminophosphonates Document date: 2015_11_17
ID: 25dwlzpy_14
Snippet: The antiviral activity was expressed as the EC 50 : the compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. The cytotoxicity of the tested compounds toward the uninfected host cells was defined as the minimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of normal cell morphology. The 50% cytotoxic concentration (CC 50 ), causing a 50% decrease in cell via.....
Document: The antiviral activity was expressed as the EC 50 : the compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. The cytotoxicity of the tested compounds toward the uninfected host cells was defined as the minimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of normal cell morphology. The 50% cytotoxic concentration (CC 50 ), causing a 50% decrease in cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay system. The tested compounds (4a-j, 5a-j) displayed no antiviral activity against the different viruses tested except for compounds 4b and 4c that showed a slight inhibition of respiratory syncytial virus replication ( Table 2 ) and compounds 5c, 5f, and 5g that displayed weak activity against both TK þ and TK À VZV strains (see Supporting Information). Although compound 4h had some activity against Coxsackie virus B4 in Vero cell cultures, no activity was seen in HeLa cells (Tables 2 and 3 ).
Search related documents:
Co phrase search for related documents- antiviral activity and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and cell morphology: 1, 2, 3
- antiviral activity and cell viability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and compound concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- antiviral activity and Coxsackie virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- antiviral activity and cytotoxic concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and different virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and HeLa cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral activity and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral activity and MCC minimum cytotoxic concentration: 1
- antiviral activity and minimum cytotoxic concentration: 1, 2, 3
- antiviral activity and plaque formation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- assay system and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- assay system and cell viability: 1, 2, 3, 4, 5, 6, 7
- assay system and Coxsackie virus: 1
- assay system and different virus: 1, 2, 3, 4, 5
- assay system and host cell: 1, 2, 3, 4
- assay system and plaque formation: 1
- cell culture and plaque formation: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date